MedTrace Logo

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

NCT00426803 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2017-01-18

No results posted yet for this study

Summary

This trial is conducted in North America, Europe, Asia and Oceania. The purpose of this study is to evaluate safety and efficacy of Recombinant Factor VIIa in patients with acute intracerebral bleeding.

Conditions

  • Acquired Bleeding Disorder
  • Intracerebral Haemorrhage

Interventions

DRUG

activated recombinant human factor VII

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-08-31
Primary Completion
2004-06-30
Completion
2004-06-30

Countries

  • Australia
  • Austria
  • Belgium
  • Canada
  • Denmark
  • Finland
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Singapore
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00426803 on ClinicalTrials.gov